2-[1-(1-ethyl-1H-imidazol-2-ylmethyl)-1H-imidazol-2-yl]-6-fluoropyridine | 624746-61-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[1-(1-ethyl-1H-imidazol-2-ylmethyl)-1H-imidazol-2-yl]-6-fluoropyridine
• 英文别名: 2-[1-[(1-Ethylimidazol-2-yl)methyl]imidazol-2-yl]-6-fluoropyridine
• CAS: 624746-61-8
• 化学式: C₁₄H₁₄FN₅
• 分子量: 271.297
• InChiKey: BBPRTYKQAOSOML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  48.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Substituted imidazole derivatives: GABAA receptor ligands
  申请人：Neurogen Corporation

  公开号：US20040002608A1

  公开（公告）日：2004-01-01

  Substituted imidazole derivatives that bind to GABA A receptors are provided. Such compounds may be used to modulate ligand binding to GABA A receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABA A receptors (e.g., receptor localization studies).

  提供了结合到GABAA受体的取代咪唑衍生物。这些化合物可用于调节体内或体外GABAA受体的配体结合，并在治疗人类、驯养伴侣动物和家畜动物的各种中枢神经系统（CNS）疾病中特别有用。本文提供的化合物可以单独或与一个或多个其他CNS药剂结合使用，以增强其他CNS药剂的作用。提供了用于治疗此类疾病的药物组合物和方法，以及用于检测GABAA受体（例如受体定位研究）的配体的使用方法。
• SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS
  申请人：NEUROGEN CORPORATION

  公开号：EP1499608A1

  公开（公告）日：2005-01-26
• US7030144B2
  申请人：——

  公开号：US7030144B2

  公开（公告）日：2006-04-18
• [EN] SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS<br/>[FR] DERIVES D'IMIDAZOLE SUBSTITUES: LIGANDS DU RECEPTEUR GABAA
  申请人：NEUROGEN CORP

  公开号：WO2003093263A1

  公开（公告）日：2003-11-13

  Substituted imidazole derivatives that bind to GABAA receptors are provided. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies). (Formula I)